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Abstract
Background: Current studies report that aberrations in epigenetic regulators or chromatin modifications are related
to tumor development and maintenance. EZH2 (Enhancer of zeste homolog 2) is one of the catalytic subunits of
Polycomb repressive complex 2, a crucial epigenetic regulator. EZH2 has a master regulatory function in such
processes as cell proliferation, stem cell differentiation, and early embryogenesis. In humans, EZH2 is linked to
oncogenic function in several carcinomas, including breast cancer, and dysregulation of EZH2 has been particularly
associated with loss of differentiation and the development of poorly differentiated breast cancer. In our present
study, we were interested in determining whether EZH2 is increased in canine mammary tumors, which show
similarities to human breast cancer.
Results: Investigation of the expression of EZH2 in canine mammary tumors revealed that EZH2 protein was
overexpressed in canine mammary carcinomas, as in human breast cancer. In addition, the immunohistochemical
expression level of EZH2 was associated with the degree of malignancy in canine mammary carcinoma. This is the
first report to describe EZH2 expression in canine mammary tumors.
Conclusions: Because the expression of EZH2 was similar in canine mammary carcinoma and human breast cancer,
spontaneous canine mammary tumors may be a suitable model for studying EZH2 and treatment development.
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Background
Breast cancer is expected to be the most common malig-
nancy among women in the United States in 2015 [1].
Although several prognostic markers in human breast
cancer have been investigated, only a small number of
markers are in clinical use, possibly because of a poor
correlation between the findings of animal studies and
clinical trials. Therefore, there is a need for more appro-
priate therapeutic targets and additional models to im-
prove the understanding and biological characterization
of human breast cancer and therapeutic development.
EZH2 is a catalytic subunit of the epigenetic regulator
Polycomb repressive complex 2 (PRC2). PRC2, which
includes EZH2, suppressor of zeste 12 (SUZ12), and
embryonic ectoderm development (EED), trimethylates
histone 3 lysine residue 27 (H3K27) and leads to silen-
cing of genes involved in processes such as stem cell
maintenance and tumor progression without DNA
sequence modification [2–4]. Recently, overexpression
or mutation of EZH2 have been found in a wide range
of human tumors, including breast, prostate, urinary
bladder, ovarian, lung, gastric cancer, renal cell carcin-
oma, and glioblastoma [5–12]. The evidence indicates
that EZH2 plays a role in the initiation, development,
progression, and metastasis of cancer and drug resist-
ance [13]. In particular, EZH2 has been connected to the
aggressiveness of breast cancer [14, 15]. In addition,
EZH2 has been reported to be an adverse prognostic
marker for breast cancer and an index of an unfavorable
tamoxifen outcome [16–18]. A correlation between loss
of differentiation and deregulated expression of EZH2
has also been proposed in human breast cancer [19].
Recent evidence implicates EZH2 in transcriptional acti-
vation, but the mechanisms are not clearly defined [20].
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In order to investigate the feasibility of an additional
animal model to improve our understanding of EZH2,
we collected and investigated naturally occurring canine
mammary tumors (CMTs). Mammary tumors are the
most commonly diagnosed neoplasms in female dogs
and nearly 50 % are malignant [21, 22]. One study has
found an annual incidence of mammary tumors of
16.8–47.7 % (benign) and 47.5 % (malignant) [23]. This
incidence is greater than that of human breast cancers.
Dog and human lineages are similar in terms of both
nucleotide divergence and rearrangements [24] and
dogs have been suggested as additional tumor models
[25, 26]. Although histomorphological features may dif-
fer between human breast cancer and CMTs, they share
many similarities in terms of age of onset, risk factors,
molecular marker expression, behavior, and prognosis
[27–30]. In addition, the incidence of CMTs is suffi-
ciently high to secure proper number of subjects in
clinical trials and the size of dogs makes multimodality
protocols feasible [31]. Therefore, it is expected that
the study of cancer using mammary tumors of domes-
ticated dog might provide new insights into cancer
understanding and therapy development.
The purpose of our present study was to investigate
EZH2 in CMTs. We found that EZH2 is overexpressed
in clinical samples of canine mammary carcinomas.
Results
Histological evaluation
The clinical and morphologic features of the 74 mam-
mary gland cases were identified (Table 1). There were
five non-neoplastic lesions including lobular hyperplasia
and duct ectasia. Sixty-nine CMT cases showed benign
morphological features (3 cases, 4 %) and malignant
features (66 cases, 96 %) such as carcinoma with simple
tubular or tubulopapillary type, complex type, mixed
type, solid type, anaplastic and inflammatory carcinoma,
mucinous carcinoma, lipid-rich carcinoma, and comedo-
carcinoma (Fig. 1). The most common type of carcinoma
identified was the complex type (26 cases, 39 %),
followed by mixed type (18 cases, 27 %) and simple
tubular type (12 cases, 18 %). Canine mammary car-
cinomas exhibited a malignancy ranging from 1–3 as
follows: 1 (38 cases, 58 %), 2 (18 cases, 27 %), and 3
(10 cases, 15 %).
Immunohistochemistry
We were interested in determining whether EZH2 is
dysregulated in CMTs, which are similar to human
breast cancers. In immunohistochemical analyses, there
was negative or weak nuclear staining in normal (Fig. 2a)
and non-neoplastic mammary tissues. Clear nuclear
staining for EZH2 could be observed in CMTs (Fig. 2b-f).
The intensity of nuclear pattern was especially strong
in comedocarcinoma (Fig. 2e), anaplastic carcinoma
(Fig. 2f ), and solid carcinoma. Carcinomas showed
higher EZH2 expression level than hyperplastic lesions
(Fig. 3). High expression of EZH2 was found to be asso-
ciated with mammary carcinoma malignancy (Table 2,
Fig. 4). We sorted each grade of carcinomas according
to the expression level of EZH2 to clarify the associ-
ation between grade of malignancy and EZH2 expres-
sion. Malignancy grade 1 was found in 2 cases (5 %) of
EZH2 score 0,19 (50 %) of EZH2 score 1, 16 (42 %) of
EZH2 score 2, and 1 (3 %) of EZH2 score 3. Malignancy
grade 2 was seen in 3 cases (17 %) of EZH2 score 1, 7
Table 1 Demographics of canine mammary cases
Type Non-neoplastic lesion Benign tumor Malignant tumor









Total 4 1 5 3 26 18 12 3 2 61
Mean age, year 8 14 9 6 11 10 10 12 10 11
Malignancy grade, no.
1 - - - - 15 15 7 0 0 37
2 - - - - 9 1 4 1 0 15
3 - - - - 2 2 1 2 2 9
Mean - - - - 1.5 1.3 1.5 2.7 3 1.5
EZH2 score, no.
0 1 1 2 0 0 1 0 0 0 1
1 2 0 2 2 8 9 4 0 0 21
2 1 0 1 1 12 6 4 2 0 24
3 0 0 0 0 6 2 4 1 2 15
Mean 1 0 0.8 1.3 1.9 1.5 2 2.3 3 1.9
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(39 %) of EZH2 score 2, and 8 (44 %) of EZH2 score 3.
Malignancy grade 3 was present in no cases of EZH2
score 1, 2 (20 %) of EZH2 score 2, and 8 (80 %) of
EZH2 score 3. According to these criteria, 99 % cases
of CMTs had elevated EZH2 expression. It did not
show any relationship within the most frequent three
carcinoma types (Complex, mixed and tubular type) of
this study (Fig. 5).
Western blotting
We used immunoblotting to compare our immunohisto-
chemistry and molecular data and further investigate the
correlations between the grade of malignancy and the
expression levels of EZH2. Western blot analysis showed
an increase in the expression of EZH2 in the CMT
tissues compared with control non-neoplastic mammary
tissues. Grade 3 carcinomas showed higher expression of
EZH2 than grades 1 and 2 (Fig. 6, Table 3).
Discussion
Although increased expression of EZH2 has been ob-
served in aggressive solid tumors in humans, the mech-
anism involved in the mediation of tumor aggressiveness
by EZH2 remains unclear. In our current study, we char-
acterized the expression pattern of EZH2 in CMTs by
immunohistochemical staining and immunoblot analysis
of CMTs and non-neoplastic mammary tissues. We
found that EZH2 protein is increased in CMTs when
compared with non-neoplastic mammary tissues. In our
immunohistochemical analysis, tumor cells exhibited a
clear nuclear staining pattern with various expression
levels. When we compared EZH2 expression level with
the tumor malignancy grade, type of carcinoma, and
type of lesion (hyperplasia/adenoma/carcinoma) respect-
ively, only carcinoma malignancy was found to have sta-
tistically significant association with EZH2 expression.
The proportion of positive EZH2 staining increased as
the malignancy grade increased. Furthermore, there was
strong nuclear staining in anaplastic carcinoma, come-
docarcinoma which are regarded as high malignant
neoplasms between CMTs, and solid carcinoma which
reveals poor differentiation. These results are consistent
with a previous report that showed a correlation be-
tween the EZH2 expression level and aggressiveness or
poor differentiation of human breast cancer [15, 19].
We compared the immunohistochemistry results with
the immunoblotting results. EZH2 protein showed a
higher expression level in grade 3 than grade 1 mam-
mary cancers. There were some results that were incon-
sistent with the tendency for EZH2 expression to
increase with malignancy. First, the number of cases was
small and not enough to produce a powerful statistic.
We also suspected that one of the reasons for these dis-
crepancies is that there is usually prominent prolifera-
tion of the surrounding connective tissue or stroma in
CMT tissue. Therefore, homogenization of a small
portion of tissue does not always adequately represent
the epithelial tumorous component. Nonetheless, there
was a tendency for an increased expression of EZH2
with CMT malignancy evident in the immunoblotting
Fig. 1 Representative mammary carcinoma tissues with H&E staining. a Carcinoma complex type with a malignant epithelial component and a
benign myoepithelial component. b Carcinoma mixed type with a malignant epithelial component and a benign mesenchymal component
(cartilage). c Carcinoma, tubular type. The tumor cells are predominantly arranged in a tubular pattern. d Comedocarcinoma. There are necrotic
areas within the center of neoplastic cell aggregates
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results, which was consistent with the immunohisto-
chemistry results. We found no correlation between the
carcinoma type and the level of EZH2 expression,
possibly due to the relatively small number of samples of
each type of carcinoma.
Murine models such as xenograft and transgenic
mouse models have been extremely useful tools in the
study of human cancer and have provided valuable in-
sights into cancer biology and biochemistry that could
not be readily obtained with other models [32]. Despite
the importance of these murine models, they have
shown a few limitations with respect to some essential
features of human cancer, including growth periods,
immune function, genomic characterization, and the
Fig. 2 Immunohistchemistry for EZH2. a Normal mammary gland. Immunohistchemistry for EZH2 showing negative staining of the mammary gland.
b Adenoma. The intensity score of EZH2 is 1. c Carcinoma mixed type with malignancy grade 1. The intensity score of EZH2 is 1. d Carcinoma solid
type with malignancy grade 3. Diffuse nuclear staining with the intensity score 3 of EZH2. e Comedocarcinoma. The intensity score of EZH2 is 3.
f Anaplastic carcinoma. Note the strong nuclear staining of neoplastic cells with intensity score 3 of EZH2
Fig. 3 Bar graph of the immunohistochemical intensity scores of EZH2.
Carcinoma demonstrated higher expression level of EZH2 than
hyperplasia lesion (*P < 0.05)
Table 2 Correlation between malignancy grade and EZH2 score
Malignancy grade EZH2 score
1 1.4 ± 0.64
2 2.3 ± 0.77
3 2.8 ± 0.42
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significant heterogeneity of tumor cells and microenvi-
ronments. Even in recently developed patient-derived
xenograft models, a higher mutation rate than would
arise in the parent tumor, a variable transplantation fail-
ure rate, as well as increased costs are major challenges
of this approach [33]. Accordingly, dogs with naturally
occurring tumors are expected to provide an additional
value to researchers.
As the CMTs in our current study in a canine model
showed similarities to human breast cancers in terms of
EZH2 expression, we suggest that dogs with naturally
occurring CMTs could be used as animal models in
future clinical trials. Canine tumor models may help to
identify novel cancer-associated genes, further elucidate
molecular pathways in tumors, and be used in the
development of novel diagnostic, prognostic, and thera-
peutic tools [24].
No EZH2 inhibitors have been approved for the treat-
ment of human cancers to date. The methyltransferase
activity of EZH2 is not required for it to activate certain
genes. Therefore, approaches based on disrupting the
interaction between EZH2 and other factors might be
potential therapeutic targets [2]. Because EZH2 plays a
diverse role in cancers, insight into the regulation of its
signaling would likely aid the development of EZH2-
targeted therapeutics. EZH2 inhibitors are currently
being developed and clinical trials for B cell lymphoma
are ongoing [34, 35].
To our knowledge, our current study is the first to re-
port on the expression of EZH2 in CMTs. Our results
lend credence to the view that CMTs are a valuable
model for EZH2 studies. However, we have only just
begun to understand the biology and functional role of
EZH2 in CMTs, and we look forward to studies aimed at
further elucidating the mechanisms involved.
Conclusions
EZH2 is expressed in CMTs, and its levels correlate with
carcinoma malignancy.
This leads to a possibility of CMT usage as a model




Mammary gland samples were collected from 74 female
domestic dogs who had been seen at a veterinary clinic
due to a mass in the mammary gland. The canine mam-
mary tissues were surgically removed from these animals
at a mean age of 12 years (7–15 years) and were submitted
Fig. 4 Bar graph of the immunohistochemical intensity scores of
EZH2. High malignancy grade tumor showed higher expression level
of EZH2 than low grade tumor (**P < 0.01)
Fig. 5 Bar graph of the immunohistochemical intensity scores of
EZH2. There is no significant difference between three types
of carcinoma
Fig. 6 Representative immunoblots of EZH2






Choi et al. BMC Veterinary Research  (2016) 12:164 Page 5 of 7
to the University of Ulsan College of Medicine between
June 2014 and May 2015. After microscopic examination,
5 samples were diagnosed as non-neoplastic lesions
and 69 specimens were diagnosed as CMTs.
Histological evaluation
Slides were evaluated for growth pattern (ductular, papil-
lary, or solid), invasion pattern (expansile, local, regional,
nodal, or vascular), mitotic index, degree of necrosis, an-
aplasia, and inflammation. The morphologic diagnosis of
CMT was based on the classification of Goldschidt et al.
[36] Using this approach, the classification of benign
mammary tumors includes adenoma simple, intraductal
papillary adenoma, ductal adenoma, adenoma complex,
benign mixed, fibroadenoma, and myoepithelioma. Ma-
lignant classifications include carcinoma simple, carcin-
oma complex, carcinoma mixed, anaplastic carcinoma,
lipid-rich carcinoma, inflammatory carcinoma, mucinous
carcinoma, and adenosquamous carcinoma. The carcin-
oma simple class has tubular, tubulopapillary, cystic-
papillary, and cribriform subclasses. Tumors that were
too poorly differentiated to be morphologically diag-
nosed were classified as solid carcinomas. Malignancy
was evaluated using the following criteria: tumor type,
tumor size, tubular formation pattern, significant nuclear
and cellular pleomorphism, mitotic index (number of
cells with mitotic figures per 10 high-power fields from
the neoplastic area with mitotic activity), and presence
of areas of necrosis [22]. All samples were also classi-
fied according to their morphologic origin. All micro-
scopic evaluations were performed by two veterinary
pathologists.
Immunohistochemistry
Sections (3 μm) from paraffin-embedded tissue blocks of
canine mammary gland tumor tissues were mounted on
glass slides. Immunohistochemistry was performed using
an automated slide preparation system (Benchmark XT;
Ventana Medical Systems Inc., Tucson, AZ). Deparaffini-
zation, epitope retrieval, and immunostaining were per-
formed according to the manufacturer’s instructions
with cell conditioning solutions (standard, for 60 min)
and the BMK ultraVIEW diaminobenzidine detection
system (Ventana Medical Systems). Tumor sections
were stained with EZH2 (1:100, ab109398, Abcam,
Cambridge, MA) for 36 min at 37 °C, followed by Ultra-
view HRP universal Multimer for 8 min at 37 °C. Positive
signals were amplified using ultraVIEW copper, and
sections were counterstained with hematoxylin and bluing
reagent for 4 min respectively.
Immunohistochemical Evaluation of EZH2
EZH2 expression was evaluated on the slides using a
semiquantitative scoring system described previously
with some modifications [10]. Samples were evaluated
for staining intensity (0, none; 1, weakly positive; 2,
moderately positive; and 3, strongly positive).
SDS-PAGE and western blot
Approximately 10 mg of CMT tissue were prepared by
TissueLyser II (Qiagen, Valencia, CA) and suspended in
sample buffer (62 mmol/liter Tris-Cl, pH 6.8, 2 % SDS,
10 % glycerol, and 0.01 % bromophenol blue with 5 % 2-
mercaptoethanol), incubated for 5 min at 100 °C, and
then electrophoretically separated in a 12 % polyacryl-
amide mini-gel. Electrophoresis was performed in Tris-
buffered saline (TBS) at a constant current of 60 mA for
2 h. Molecular weight standards (P8502-050; GenDE-
POT) were run simultaneously. The gel was stained with
Coomassie Blue. A parallel SDS-PAGE gel was run as
described above, and the separated proteins were trans-
ferred directly by tank blotting onto a polyvinyl difluor-
ide transfer membrane (Bio-Rad Corp, Hercules, CA) for
90 min at a constant current of 80 mA. After saturation
of the nonspecific sites with 5 % nonfat milk/TBS over-
night at 4 °C, the proteins were probed with a 1:500 di-
lution of rabbit anti-EZH2 antibody (ab186006; Abcam,
Cambridge, MA) overnight at 4 °C. The blot was then
washed in 20 mM Tris-HCl, pH 7.5, and 0.14 mM NaCl
containing 0.5 % Tween 20 (TBS-Tween) and then incu-
bated for 2 h in an anti-rabbit HRP-conjugated IgG anti-
body (SC-2004; Santa Cruz, Santa Cruz, CA) diluted
1:1000 in TBS-Tween at room temperature. The immu-
noblot was exposed to an enhanced chemiluminescence
immunoassay substrate reagent (DG-WP250; DoGen,
Seoul, Korea) for 1 min to detect signals and the mem-
brane was exposed to X-ray film for 5 min. Band inten-
sity on exposed film was semi-quantified using ImageJ
software (National Institutes of Health, Bethesda, MD).
Statistical analysis
Data are expressed as the mean ± standard deviation of
the mean. Since our data were not normally distributed
in the Kolmogorov-Smirnov test, we compared the data
with the Kruskal-Wallis test, which is a non-parametric
method using the SPSS version 21 (IBM Corp., Armonk,
NY). If significant, paired comparisons were done with
the Mann Whitney test. A Bonferronic correction was
applied to correct for multiple comparisons of the pri-
mary end point.
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